Indian pharma lobby seeks 'fair chance' before its drugs are deemed non-standard

4 May 2023

A number of top Indian drugmakers have requested that the Drug Controller General of India gives pharmaceutical companies a 'fair chance' to review the quality of drug samples that have been declared 'not of standard quality' (NSQ) before publishing any drug alert.

The companies, through their association with the Indian Pharmaceutical Alliance (IPA), have also recommended a few changes in the procedure such as 'validating the genuineness' of the drugs and issuing of show-cause notice before making a public announcement.

The matter came to light after the latest alert was published on the Central Drugs Standard Control Organization (CDSCO)'s website. The alert said 48 of the 1,497 samples tested in March failed the quality parameters.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK